Article Sidebar

Volumen 24 nº 3 2021
Submitted
July 2, 2021
Published
September 30, 2021
Download
pdf (Español (España)) html (Español (España)) xml (Español (España))
Statistic
Read Counter : 955 Download : 335

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Main Article Content

Abstract

Introduction: Being an active healthcare worker is a highrisk factor for contracting the SARS-CoV-2 infection. The implementation of vaccination programs is the best option available to solve this problem. In Spain, healthcare professionals have been vaccinated as a matter of priority.
Objective: To assess, through blood antibody counts, the immunogenicity of SARS-CoV2 vaccines in dialysis personnel and related factors.
Material and Method: Observational, cross-sectional and multicentric descriptive study.
Results: 167 participants, all vaccinated with RNA vaccines. 15% have previously passed the infection. 96.4% have developed antibodies (mean of 15,776 +/-13,640). Those professionals who have previously passed the infection have a significantly higher average number of antibodies than those who have not (23,532 vs 14,381) (p=0.05). The presence of symptoms such as fatigue, headache, fever, and myalgia is also related with a significantly greater reactivity (p=0.004). There is no significant relationship between reactivity and sex, age, BMI, or workplace.
Conclusions: Immunogenicity caused by RNA vaccines administered to dialysis personnel has been almost complete. Suffering post-vaccination adverse effects such as fatigue, headaches, fever, nausea, pain, and having previously passed the infection is related to a greater reactivity, manifested by the development of an increased number of antibodies.

Keywords

coronavirus SARS-CoV-2 vaccine health care worker hemodialysis

Article Details

License

Author copyright notice

© Authors grant the publisher the non-exclusive licence to publish the work and consent to its use and distribution under the Creative Commons Attribution - NonCommercial 4.0 International (CC BY-NC 4.0) licence. Read the licensing information and the legal text here. This must be expressly stated wherever necessary.

How to Cite
1.
Guerrero-Rodríguez E, Hernán-Gascueña D, Miranda-Serrano MB, Arenas-Jiménez L, Pereira-Feijoo C, Sanjuan-Miguelsanz M. Reactogenicity and immunogenicity after inoculation of SAR-CoV-2 vaccine in dialysis care workers. Enferm Nefrol [Internet]. 2021 [cited 2025 Apr 30];24(3):[about 9 p.]. Available from: https://www.enfermerianefrologica.com/revista/article/view/4425
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Di Gennaro F, Murri R, Segala FV, Cerruti L, Abdulle A, Saracino A, et al. Attitudes towards Anti-SARS-CoV2 Vaccination among Healthcare Workers: Re¬sults from a National Survey in Italy. Viruses (con¬sultado 21 Feb 2021) Disponible en: https://doi.org/10.3390/v1303037113, (2021).
  2. Grupo de Trabajo Técnico de Vacunación COVID-19, de la ponencia de programa y registro de vacunaciones. Estrategia de vacunación frente a COVID-19 en España. Actualización 5. (consultado 14 May 2021) Disponible en:
  3. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion5_EstrategiaVacunacion.pdf (2021).
  4. The Lancet. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. The Lancet vol. 395 1011 (2020). (consultado 7 Mar 2021) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774556/.
  5. Sánchez-Álvarez E, Quiroga B, de Sequera P. Posicionamiento de la Sociedad Española de Nefrología ante la vacunación frente al SARS-CoV-2. Nefrología (consultado 4 Feb 2021) Disponible en: https://www.senefro.org/contents/webstructure/noticias/Position_statement_Vacuna_COVID_%20-%20Copy%201.pdf.
  6. Estrategia de vacunación frente a COVID-19 en España. Consejo Interterritorial. Sistema Nacional de Salud. Abril 2021 [consultado 28 Abr 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion7_EstrategiaVacunacion.pdf (2021).
  7. Baker TL, Greiner JV, Maxwell-Schmidt E, Lamothe PH, Vesonder M. Guidelines for Frontline Health Care Staff Safety for COVID-19. Journal of Primary Care and Community Health vol. 11 (2020) (consultado 3 Abr 2021) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377597/pdf/10.1177_2150132720938046.pdf.
  8. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 2021[consultado15 Mar 2021];6;397(10277):875-77 Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00448-7/fulltext.
  9. Hall VJ, Foulkes S, Saei A, Andres N, Oguti B, Charlett A. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccibe coverge in healthcare workers in England. Lancet Feb 2021 [En prensa]. Disponible en: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399.
  10. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing. 2021 Feb 26;50(2):279-83.
  11. Klimek L, Bergmann KC, Brehler R, Pfützner W, Zuberbier T, Hartmann K, et al. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI. Allergo J Int, 2021; 19:1-17. [En prensa].
  12. Abbott. AdviseDx SARS-CoV-2 IgG II. [consultado 6 Mar 2021]. Disponible en: https://www.fda.gov/media/146371/download.
  13. Actualización nº 405. Enfermedad por el coronavirus (COVID-19). Ministero de Sanidad. Gobierno de España. Jun 2021 [consultado 26 may 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_405_COVID-19.pdf13. Mallapaty S. Vaccines are curbing COVID: Data from Israel show drop in infections. Nature. 2021 Feb;590(7845):197.
  14. Estudio ENE-COVID: Cuarta Ronda. Estudio nacional de sero-epidemiología de la infección por SARS-COV-2 en España. Instituto de Salud Carlos III, Ministerio de sanidad y Ministerio de ciencia e innovación. Dic 2020 [consultado 2 Mar 2021]. Disponible en: https://www.mscbs.gob.es/gabinete-Prensa/notaPrensa/pdf/15.12151220163348113.pdf (2020).
  15. Aschwanden C. Five reasons why herd immunity for COVID is probably impossible. Nature. 2021 Mar;591(7851):520-2.
  16. Jahn M, Korth J, Dorsch O, Anastasiou OE, Roge-Hädicke Humoral response to SARS-CoV-2-vaccination with BNT162b2 (pfizer-biontech) in patients on hemodialysis. Vaccines (Basel). 2021 Apr 8;9(4):360.
  17. Monográfico vacunación COVID-19. La realidad tras los ensayos clínicos. Comité Científico del ICOMEM sobre la COVID-19, 2021 [consultado 24 May 2021]. Disponible en: https://www.icomem.es/adjuntos/adjunto_3092.1618927955.pdf.
  18. Estrategia de detección precoz, vigilancia y control de Covid-19. Instituto Carlos III. Ministerio de Sanidad. Gobierno de España. 2021 [consultado 2 Jun 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf.
  19. Vacunas COVID-19. Informe de farmacovigilancia Número 5. Agencia Española de Medicamentos y Productos Sanitarios. 2021 [consultado 27 May 2021]. Disponible en: https://www.aemps.gob.es/laAEMPS/docs/informe-farmacovigilancia-mayo- 2021.pdf?x16990.
  20. Jabal KA, Ben-Amram H, Beiruti K, Sussan C, Zarka S, et al. Impact of age gender ethnicity and prior disease status on immunogenicity following. MedRxiv. Enero 2021 [En prensa]

Most read articles by the same author(s)

Similar Articles

<< < 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 > >> 

You may also start an advanced similarity search for this article.